AU2019260793B2 - Methods for treating testicular and ovarian adrenal rest tumors - Google Patents

Methods for treating testicular and ovarian adrenal rest tumors Download PDF

Info

Publication number
AU2019260793B2
AU2019260793B2 AU2019260793A AU2019260793A AU2019260793B2 AU 2019260793 B2 AU2019260793 B2 AU 2019260793B2 AU 2019260793 A AU2019260793 A AU 2019260793A AU 2019260793 A AU2019260793 A AU 2019260793A AU 2019260793 B2 AU2019260793 B2 AU 2019260793B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019260793A
Other languages
English (en)
Other versions
AU2019260793A1 (en
Inventor
Hal GERBER
Alexis HOWERTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spruce Biosciences Inc
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019260793(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of AU2019260793A1 publication Critical patent/AU2019260793A1/en
Priority to AU2023203095A priority Critical patent/AU2023203095A1/en
Application granted granted Critical
Publication of AU2019260793B2 publication Critical patent/AU2019260793B2/en
Priority to AU2025204720A priority patent/AU2025204720A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019260793A 2018-04-27 2019-04-26 Methods for treating testicular and ovarian adrenal rest tumors Active AU2019260793B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023203095A AU2023203095A1 (en) 2018-04-27 2023-05-17 Methods for treating testicular and ovarian adrenal rest tumors
AU2025204720A AU2025204720A1 (en) 2018-04-27 2025-06-23 Methods for treating testicular and ovarian adrenal rest tumors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663951P 2018-04-27 2018-04-27
US62/663,951 2018-04-27
US201962822815P 2019-03-23 2019-03-23
US62/822,815 2019-03-23
PCT/US2019/029486 WO2019210266A1 (en) 2018-04-27 2019-04-26 Methods for treating testicular and ovarian adrenal rest tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203095A Division AU2023203095A1 (en) 2018-04-27 2023-05-17 Methods for treating testicular and ovarian adrenal rest tumors

Publications (2)

Publication Number Publication Date
AU2019260793A1 AU2019260793A1 (en) 2020-12-17
AU2019260793B2 true AU2019260793B2 (en) 2023-05-18

Family

ID=68295784

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019260793A Active AU2019260793B2 (en) 2018-04-27 2019-04-26 Methods for treating testicular and ovarian adrenal rest tumors
AU2023203095A Abandoned AU2023203095A1 (en) 2018-04-27 2023-05-17 Methods for treating testicular and ovarian adrenal rest tumors
AU2025204720A Pending AU2025204720A1 (en) 2018-04-27 2025-06-23 Methods for treating testicular and ovarian adrenal rest tumors

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023203095A Abandoned AU2023203095A1 (en) 2018-04-27 2023-05-17 Methods for treating testicular and ovarian adrenal rest tumors
AU2025204720A Pending AU2025204720A1 (en) 2018-04-27 2025-06-23 Methods for treating testicular and ovarian adrenal rest tumors

Country Status (10)

Country Link
US (6) US11304950B2 (https=)
EP (3) EP4438124A3 (https=)
JP (1) JP7427655B2 (https=)
CN (1) CN112423747A (https=)
AU (3) AU2019260793B2 (https=)
BR (1) BR112020024062A2 (https=)
CA (1) CA3098562A1 (https=)
ES (1) ES2991516T3 (https=)
MX (1) MX2020011344A (https=)
WO (1) WO2019210266A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
EP4438124A3 (en) 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
TW202116324A (zh) * 2019-07-19 2021-05-01 美商雲杉生物科技股份有限公司 治療先天性腎上腺增生之方法
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
BR112023002497A2 (pt) * 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
JP2023540223A (ja) * 2020-08-26 2023-09-22 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
MX2024006064A (es) * 2021-11-19 2024-05-30 Spruce Biosciences Inc Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
US11708372B2 (en) * 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020877A1 (en) * 2014-01-21 2017-01-26 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
ATE177101T1 (de) 1992-12-17 1999-03-15 Pfizer Pyrrolopyrimidine als crf antagonisten
JPH0971528A (ja) * 1995-07-05 1997-03-18 Hayashibara Biochem Lab Inc 抗腫瘍剤
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP3356291B2 (ja) 1996-02-07 2002-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
IL127566A0 (en) 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
EP1218381B1 (en) 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
JP2003516353A (ja) 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
BR0208357A (pt) 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
US20050085479A1 (en) 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
CA2547639A1 (en) 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
CA2550948A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
WO2005079868A2 (en) 2004-02-13 2005-09-01 Sb Pharmco Puerto Rico Inc Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2006227300B2 (en) 2005-03-21 2012-02-02 Eli Lilly And Company Imidazopyridazine compounds
CA2644445A1 (en) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
AU2007297481B2 (en) 2006-09-20 2012-03-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
EP2094709B1 (en) * 2006-09-20 2010-09-15 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
WO2010039678A1 (en) 2008-10-02 2010-04-08 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP4718073A2 (en) 2008-12-24 2026-04-01 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
HK1207304A1 (en) 2012-04-23 2016-01-29 Hmnc Value Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
AU2016242867B2 (en) 2015-03-31 2020-11-05 May Health Us Inc. Methods and systems for the manipulation of ovarian tissues
EA202090321A1 (ru) * 2017-08-14 2020-09-24 Спрюс Биосайнсес, Инк. Антагонисты рецептора кортикотропин-рилизинг фактора
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
EP4438124A3 (en) 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
TW202116324A (zh) 2019-07-19 2021-05-01 美商雲杉生物科技股份有限公司 治療先天性腎上腺增生之方法
BR112023002497A2 (pt) 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
MX2024006064A (es) 2021-11-19 2024-05-30 Spruce Biosciences Inc Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020877A1 (en) * 2014-01-21 2017-01-26 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Also Published As

Publication number Publication date
AU2025204720A1 (en) 2025-07-10
CA3098562A1 (en) 2019-10-31
US12569491B2 (en) 2026-03-10
CN112423747A (zh) 2021-02-26
US20250177404A1 (en) 2025-06-05
EP3784233B1 (en) 2024-06-05
WO2019210266A1 (en) 2019-10-31
US20210038604A1 (en) 2021-02-11
US12576084B2 (en) 2026-03-17
AU2019260793A1 (en) 2020-12-17
US20250195527A1 (en) 2025-06-19
US20220211711A1 (en) 2022-07-07
EP4438124A2 (en) 2024-10-02
EP3784233A1 (en) 2021-03-03
US20250064812A1 (en) 2025-02-27
JP2021522340A (ja) 2021-08-30
EP3784233C0 (en) 2024-06-05
EP4438124A3 (en) 2024-12-18
MX2020011344A (es) 2021-02-09
EP4643950A2 (en) 2025-11-05
US11304950B2 (en) 2022-04-19
EP3784233A4 (en) 2022-03-02
BR112020024062A2 (pt) 2021-02-09
JP7427655B2 (ja) 2024-02-05
US20250177403A1 (en) 2025-06-05
EP4643950A3 (en) 2026-01-14
ES2991516T3 (es) 2024-12-03
AU2023203095A1 (en) 2023-06-08
US12569490B2 (en) 2026-03-10

Similar Documents

Publication Publication Date Title
US12569490B2 (en) Methods for treating testicular and ovarian adrenal rest tumors
US11964941B2 (en) 5-Bromo-indirubins
CA2853729A1 (en) Novel compositions and methods for treating cancer
US20220274964A1 (en) 5-bromo-indirubins
WO2019236631A1 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
US12590056B2 (en) IGF2BP2 inhibitors and uses thereof
HK40040045A (en) Methods for treating testicular and ovarian adrenal rest tumors
HK40040045B (en) Methods for treating testicular and ovarian adrenal rest tumors
US11213510B2 (en) Thioindirubins
HK1220197B (en) 5-bromo-indirubins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)